---
title: "iSpecimen (ISPC.US) Surges Over 22% Intra-day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284904644.md"
description: "iSpecimen（ISPC.US）现价 $6.400，当日 +22.37%，日内涨幅显著，市值 0.04 亿。公司专注于医学样本采购。今日涨势主要受公司宣布进行 1 比 40 反向股票拆分影响，市场对拆股消息做出快速反应。近期未见其他重大催化，异动或与短线资金流动有关。"
datetime: "2026-05-01T13:40:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284904644.md)
  - [en](https://longbridge.com/en/news/284904644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284904644.md)
---

# iSpecimen (ISPC.US) Surges Over 22% Intra-day

iSpecimen (ISPC.US) is trading at $6.400, up **22.37%** intraday, with a significant price surge and a market cap of $4 million.

The company specializes in medical specimen procurement. The stock’s sharp rise today is mainly driven by its 1-for-40 reverse stock split announcement, prompting swift market reaction. No other major catalysts have been reported recently; the move may relate to short-term capital flows.

### Related Stocks

- [ISPC.US](https://longbridge.com/en/quote/ISPC.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [ISpecimen Announces Private Placement Worth $2.5 Mln](https://longbridge.com/en/news/285937495.md)
- [iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement | ISPC Stock News](https://longbridge.com/en/news/285787160.md)
- [Guardant Health Says US FDA Approved Liquid Biopsy Test](https://longbridge.com/en/news/287069625.md)
- [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)